Phase 3 N=55 Comparison of Intraoperative Warming Devices
Total Knee Arthroplasty
Primary: Sublingual Temperature. — 36.38; 36.73 C
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=356 Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).
Generalized Anxiety Disorder
Primary: Change in Hamilton Anxiety Rating Scale (HAM-A) Total Scores — -7.6; -6.4 score on scale
Phase 3 N=460 A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease
Pelvic Inflammatory Disease
Primary: Clinical Response 7 to 14 Days After Completion of Study Drug Therapy in Per Protocol (PP) Population — 152; 155; 42; 35 participants
Phase 3 N=73 Clinical Research Study Efficacy of a Prototype Oral Rinse
Dental Plaque
Primary: Gingival Index — 1.90; 1.84 Units on a scale — p=0.005
Phase 3 N=345 Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17
Attention Deficit Disorder With Hyperactivity
Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Score at Up to 5 Weeks — -15.93; -16.03; -18.51; -8.51 Units on a Scale…
Phase 3 N=547 Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
Colorectal Neoplasms
Primary: Time to Progression (TTP) at Primary Completion: FOLFIRI and mIFL — 8.18; 6.01 months — p=0.0152
Phase 3 N=12,167 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
Cervical Cancer · Genital Warts
Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…
Phase 3 N=217 SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms
ADHD
Primary: Change From Baseline in the Oppositional Subscale of the Conners' Parent Rating Scale-Revised Long Form (CPRS-R:L) Score at Up to 8 Weeks — -10.8; -7.0 Units on a scale…
Phase 3 N=226 Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
Epilepsy, Partial
Primary: The Percentage of Participants in the 300 mg/Day Dose Group Who Prematurely Discontinued the Study Between Study Visit 5 (Approximately Week 7) and Visit 9 (End of the…
Phase 3 N=291 A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy
Bunionectomy · Pain · Postoperative Pain
Primary: Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity. — 46.2; 102.5; -17.5 units — p=<0.0001
Phase 3 N=802 A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain
Low Back Pain
Primary: Treatment Responders Based on the Numerical Rating Scale-Pain (NRS-Pain) — 254; 218; 142; 178 participants — p=0.008
Phase 3 N=5,759 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Cervical Cancer · Genital Warts
Primary: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer — 0; 1.2 incidence rate per 100…
Phase 3 N=203 A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis
Psoriasis
Primary: Number of Subjects With Psoriasis Area and Severity Index (PASI) 75 Response at 16 Weeks — 144; 47 participants
Phase 3 N=156 Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease
Parkinson Disease
Primary: Percentage of Patients Who Successfully Switched From Pramipexole Immediate Release (IR) to Pramipexole ER After a Possible Dose Adaptation, Full Analysis Set (FAS)…
Phase 3 N=324 Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)
Allergic Rhinitis
Primary: The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days. — -0.68; -0.57 Units on a scale — p=0.102